EMBEDA Drug Patent Profile

Which patents cover Embeda, and what generic alternatives are available?

Embeda is a drug marketed by Alpharma Pharms and is included in one NDA. There are seven patents protecting this drug and four Paragraph IV challenges.

This drug has seventy-four patent family members in twenty-three countries.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this compound. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Embeda

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 19, 2027. This may change due to patent challenges or generic licensing.

There are four Paragraph IV patent challenges for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for EMBEDA

International Patents:	74
US Patents:	7
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for EMBEDA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EMBEDA	Extended-release Capsules	morphine sulfate; naltrexone hydrochloride	20 mg/0.8 mg	022321	1	2018-08-16
EMBEDA	Extended-release Capsules	morphine sulfate; naltrexone hydrochloride	30 mg/1.2 mg 50 mg/2 mg 80 mg/3.2 mg	022321	1	2010-05-28
EMBEDA	Extended-release Capsules	morphine sulfate; naltrexone hydrochloride	60 mg/2.4 mg	022321	1	2010-05-25
EMBEDA	Extended-release Capsules	morphine sulfate; naltrexone hydrochloride	100 mg/4 mg	022321	1	2010-05-03

US Patents and Regulatory Information for EMBEDA

EMBEDA is protected by seven US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-006	Aug 13, 2009		DISCN	Yes	No			Y
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-005	Aug 13, 2009		DISCN	Yes	No			Y
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-004	Aug 13, 2009		DISCN	Yes	No			Y

International Patents for EMBEDA

When does loss-of-exclusivity occur for EMBEDA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Denmark

Hungary

Japan

Poland

Slovenia

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EMBEDA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	133862
Austria	167629
Australia	4773290

Summary

Last updated: February 3, 2026

Embeda (morphine sulfate extended-release and naltrexone hydrochloride) is an opioid analgesic used for managing severe pain in opioid-tolerant patients. Its investment profile depends on regulatory, market, and competitive factors. Key considerations include patent protections, market demand for opioid analgesics, regulatory environment, and trends toward abuse-deterrent formulations. As of 2023, Embeda faces patent cliffs and increased scrutiny over opioid safety, affecting its long-term commercial potential.

---

What is Embeda’s Market Position and Revenue Outlook?

Embeda, marketed primarily by Pfizer (acquired through its acquisition of world-wide rights from Matrix on 2010), competes within the extended-release opioid pain management segment. Its unique feature includes abuse-deterrent properties due to naltrexone, which blocks opioid effects if tampered with.

Market Size and Competition: The global opioid analgesics market was valued at approximately $11 billion in 2022, projected to grow at a compound annual growth rate (CAGR) of 4% through 2030. Embeda targets opioid-tolerant patients with chronic pain, a market segment with estimated annual sales of $2.5 billion, but it faces competition from generic formulations and abuse-deterrent alternatives like Xtampza ER and OxyContin.

Revenue Trajectory: Pfizer did not publicly disclose Embeda’s specific sales after its initial launch, but estimates suggest peak sales of $200 million annually in the US in 2014-2015, declining due to patent expiration and increased regulatory concerns. Now, Embeda's revenue is likely under $50 million annually, with significant erosion due to generics and regulatory restrictions.

---

How Do Patents and Regulatory Factors Affect Embeda’s Investment Potential?

Patent Life and Exclusivity: Embeda was granted exclusivity with patent protections through 2019, with additional formulation patents extending to 2024 in the US. Post-2024, generic versions have entered the market, significantly reducing pricing power and revenue.

Regulatory Environment: The US FDA's increased scrutiny of opioids in recent years introduces risks for Embeda, especially around abuse-deterrent claims. While Embeda has abuse-deterrent properties, the FDA has shifted toward more cautious prescribing practices, limiting the product’s growth prospects.

Legal Risks: Opioid litigation and federal investigations have increased. Insurance companies and payers are increasingly favoring non-opioid alternatives, further constraining market share.

---

What Are the Key Drivers and Risks Behind Embeda’s Fundamentals?

Drivers:

• Growing need for abuse-deterrent opioids amid opioid epidemic awareness.
• Potential niche market among opioid-tolerant patients requiring extended-release pain control.
• Pfizer’s ongoing efforts to back proprietary formulations with patents and clinical data.

Risks:

• Patent expiration leading to price erosion and loss of exclusivity.
• Increased regulatory oversight and potential for label restrictions.
• Market shift toward non-opioid pain treatments and non-addictive alternatives.
• Competition from generics and newer abuse-deterrent formulations with superior delivery systems.

---

What Are the Investment Considerations for Embeda?

Current Valuation: Embeda’s market capitalization is low relative to its peak due to patent expirations and revenue declines. Pfizer no longer emphasizes Embeda as a core product, indicating limited growth potential.

Growth Potential: Limited. Small niche for abuse-deterrent opioids exists, but regulatory headwinds and patent expiry constrain upside.

Valuation Metrics: With revenue under $50 million and minimal R&D investments post-2019, Embeda may be valued mainly as an asset or within a broader opioid portfolio.

Strategic Value: Could serve as part of a diversified portfolio of pain management assets, particularly if patent litigation or exclusivity extensions temporarily bolster commercial viability.

---

What Are Future Outlooks and Market Trends Affecting Embeda?

• Regulatory Trends: More stringent opioids prescribing guidelines could decrease market size.
• Market Shift: Rising adoption of non-opioid analgesics, including NSAIDs, antidepressants, and nerve modulators.
• Pipeline & Innovation: Limited pipeline or reformulations for Embeda, reducing prospects for renewal or new indications.
• Legal Climate: Ongoing opioid litigation could impact Pfizer’s overall opioid-related assets; Embeda may be affected indirectly.

---

Key Takeaways

• Embeda has a niche role as an abuse-deterrent opioid, but its revenue prospects are limited due to patent expiry, regulatory changes, and market competition.
• The product’s peak sales in the mid-2010s suggest it no longer holds a significant position in Pfizer’s portfolio.
• Regulatory and societal factors create headwinds for the growth of abuse-deterrent opioids.
• Potential investors or partners should view Embeda as a declining asset with minimal near-term growth unless significant regulatory or patent strategy shifts occur.
• Broader market dynamics favor non-opioid pain management options, further constraining Embeda’s future.

---

FAQs

1. What is Embeda’s primary mechanism of abuse deterrence?

   Embeda combines an extended-release formulation of morphine sulfate with naltrexone hydrochloride. If tampered with (e.g., crushed or dissolved), naltrexone is released, blocking the opioid effects and deterring abuse.

2. When do Embeda’s patents expire?

   Original patents expired in 2019. Additional formulation patents extended protection into 2024 in the US, after which generic versions entered the market.

3. How has market demand for Embeda changed in recent years?

   Sales have declined significantly since 2015 due to patent expiry, increased regulatory restrictions, and the shift toward non-opioid therapies.

4. What are competitors offering in the abuse-deterrent opioid space?

   Competitors include Xtampza ER (by Egalet), OxyContin (by Purdue Pharma), and reformulated versions of other opioids, often with more advanced abuse-deterrent technologies.

5. Is Embeda a viable long-term investment?

   Given current market conditions, patent expirations, and regulatory headwinds, Embeda carries limited long-term growth prospects and is better viewed as a marginal or declining asset.

---

Sources

[1] IQVIA, "Global Opioid Market Report," 2022.
[2] Pfizer corporate filings, 2022.
[3] US Food and Drug Administration, "Opioid Analgesic Market Review," 2022.
[4] Evaluate Pharma, "Pain Management Drugs Market Overview," 2023.
[5] Bloomberg Industry Analysis, "Abuse-Deterrent Opioids," 2023.